Cassava Sciences Inc

NASDAQ: SAVA
$32.18
+$6.13 (+23.5%)
Closing Price on November 21, 2024

SAVA Stock Chart and Intraday Price

SAVA Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN, TX, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 971.45M USD
Shares Outstanding 42,236,900
Cassava Sciences Inc is a biotech firm focused on developing treatments for neurodegenerative diseases, particularly Alzheimer's. Its flagship product, simufilam, has shown promise in early clinical trials. Additionally, Cassava is working on SavaDx, a diagnostic tool aimed at early detection of Alzheimer's through blood tests. Originally known as Pain Therapeutics, the company rebranded in 2019 to better reflect its focus on neuroscience. Based in Austin, Texas, Cassava Sciences continues to pioneer in the field of neurology since its inception in 1998.

SAVA Articles

Meme stocks traded well-mixed at midday Thursday. The morning's most surprising turn came from a stock that missed estimates and gave lower guidance but still traded higher.
Meme stock winners far outnumbered losers on Tuesday, and one of those winners is posting another big gain in Wednesday's premarket.
On Tuesday, the biggest winner among meme stocks was Cassava Sciences, while Camber Energy took the biggest hit.
Retail investors may be revving up a short squeeze on a stock that was hammered on Monday.
U.S. retail investors now own 12 times more stock than do hedge funds, and Americans have a greater percentage of their money in savings and stock portfolios than at any time since 1950.
An FDA directive has hammered a coronavirus vaccine maker Friday morning as a new variant of the infection is discovered in South Africa.
Here's a look at why five favorite retail stocks were all trading up by double digits at noontime Friday.
A federal investigation into one company's research data has caused its stock to crater, while a rebuttal of a short seller's claims have lifted another.
EV stocks were losing some of their recent gains, and one biotech has announced a new federal investigation.
A company developing a treatment for Alzheimer's disease got a big boost Thursday when a journal in which the company published a report said it found no basis for allegations of data and image...